376 related articles for article (PubMed ID: 22296221)
1. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
Ho P; Sherman P; Grigg A
Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
[TBL] [Abstract][Full Text] [Related]
2. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.
Silvestri F; Fanin R; Velisig M; Barillari G; Virgolini L; Zaja F; Russo D; Baccarani M
Tumori; 1994 Dec; 80(6):453-8. PubMed ID: 7534963
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
Dotti G; Stella CC; Mangoni L; Cottafavi L; Caramatti C; Almici C; Rizzoli V
Haematologica; 1995; 80(2):142-5. PubMed ID: 7543069
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.
Minuk LA; Monkman K; Chin-Yee IH; Lazo-Langner A; Bhagirath V; Chin-Yee BH; Mangel JE
Leuk Lymphoma; 2012 Jan; 53(1):57-63. PubMed ID: 21740297
[TBL] [Abstract][Full Text] [Related]
5. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
Evens AM; Cilley J; Ortiz T; Gounder M; Hou N; Rademaker A; Miyata S; Catsaros K; Augustyniak C; Bennett CL; Tallman MS; Variakojis D; Winter JN; Gordon LI
Br J Haematol; 2007 Jun; 137(6):545-52. PubMed ID: 17459049
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.
Younes A; Fayad L; Romaguera J; Pro B; Goy A; Wang M
Eur J Cancer; 2006 Nov; 42(17):2976-81. PubMed ID: 17008093
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.
Graczyk J; Cheung MC; Buckstein R; Chan K
Leuk Lymphoma; 2014 Jan; 55(1):56-62. PubMed ID: 23597142
[TBL] [Abstract][Full Text] [Related]
8. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
9. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia.
Gupta S; Singh PK; Bhatt ML; Pant MC; Gupta R; Negi MP
Biosci Trends; 2010 Oct; 4(5):273-8. PubMed ID: 21068482
[TBL] [Abstract][Full Text] [Related]
11. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
Russo F; Corazzelli G; Frigeri F; Capobianco G; Aloj L; Volzone F; De Chiara A; Bonelli A; Gatani T; Marcacci G; Donnarumma D; Becchimanzi C; de Lutio E; Ionna F; De Filippi R; Lastoria S; Pinto A
Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor.
Merdin A; Çakar MK; Dal MS; Mert D; Yıldız J; Başçı S; Bakırtaş M; Darçın T; Şahin D; Ulu BU; Yiğenoğlu TN; Batgi H; Tetik A; İskender D; Altuntaş F
J Oncol Pharm Pract; 2020 Jun; 26(4):929-932. PubMed ID: 31822199
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
15. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD.
Rueda A; Sevilla I; Gumà J; Ribelles N; Miramón J; De Las Nieves MA; Márquez A; Alba E
Leuk Lymphoma; 2001 Apr; 41(3-4):353-8. PubMed ID: 11378548
[TBL] [Abstract][Full Text] [Related]
16. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
Bobey N; Woodman RC
Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
[TBL] [Abstract][Full Text] [Related]
17. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
18. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.
Zinzani PL; Martelli M; Tura S; Mandelli F
Haematologica; 1993; 78(1):40-3. PubMed ID: 7684011
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
Kushner BH; Heller G; Kramer K; Cheung NK
Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]